Cantor Fitzgerald Downgrades Sunesis Pharmaceuticals Inc. (SNSS) to Hold
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/28/2026
- Wall Street ends lower after Fed Chair Warsh reaffirms inflation fight
- Fed chair Warsh kicks off Jackson Hole keynote address
- PayPal tumbles as Advent, Stripe said to drop $50 bln pursuit
- Oil settles lower on clues about Fed policy, rumors of Hormuz deal
- Dollar jumps after Warsh comments, set for weekly gain
- First Financial to acquire Hickory Point Bank in $111.3M deal
- McKesson reports cybersecurity incident affecting its information systems
- Affirm Holdings (AFRM) Tops Q4 EPS by $3.77, Beats on Revenue
- Nasdaq, S&P 500 lifted by Nvidia's forecast; investors eye speech by Fed's Warsh
- BioNTech ends colorectal cancer mRNA therapy trial early
Sunesis Pharmaceuticals Announces Regulatory Update
July 23, 2015 4:06 PM EDTCompany to Proceed Expeditiously With Marketing Authorization Application in Europe and Will Evaluate Regulatory and Clinical Strategies to Gain Marketing Approval in the U.S.
Sunesis to Host Conference Call Today at 5:00 PM Eastern Time
SOUTH SAN FRANCISCO, Calif., July 23, 2015 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced regulatory updates from its interactions with the European Medicines Agency (EMA) and U.S. Food and Drug Administration (FDA) regarding a potential path toward marketing authorization for vosaroxin as a treatment for acute myeloid... More
